Form 4 for STOK Stoke Therapeutics, Inc.
Accepted 2024-12-11 00:00:00 ET · period of report 2024-12-09 · accession 0001415889-24-028928 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-11 | 2024-12-09 | STOK | Kaye Edward M. MD | CEO, Dir | S - Sale | $12.99 | -6,786 | 61.9K | -10% | -$88.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-09 | S | D | 6,786 | $12.99 | 61,885 | D | — | — | (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.13 per share, inclusive. |